• Sofia Ioannidou joined Andera Partners’ Andera Life Sciences team in 2009 as an Associate. She was promoted to Partner in 2019.
  • Prior to Andera Partners, Sofia was part of the Life Sciences team of L.E.K. Consulting London, from 2006 to 2008, having started her career in R&D with Boston-based Eyetech Pharmaceuticals, Inc., from 2003 to 2006.
  • Since 2009, she has actively contributed to a number of investments, trade sales and IPOs. Sofia currently serves on the board of Bioptimus, Nouscom, Tubulis, Tricares, and Exciva and has previously served on the boards of Avalyn, LogicBio, Sanifit and PegaOne.
  • She holds a PhD in Cell Biology from Cancer Research UK and an MBiochem from the University of Oxford.
  • Sofia is a native Greek speaker and also speaks English, French and Spanish.

4 languages spoken

Investments of Sofia

10.2025 - andera Life Sciences In portfolio

Adcytherix

Biotech company focused on the development of antibody drug conjugates for high unmet need diseases such as cancer

01.2025 - andera Life Sciences In portfolio

Bioptimus

Bioptimus is building the first universal AI foundation model that connects biology at its different scales – from molecules to cells, tissues, and whole organisms

11.2023 - andera Life Sciences In portfolio

Nouscom

Clinical stage immuno-oncology company

05.2022 - andera Life Sciences In portfolio

Tubulis

Antibody drug conjugates for the treatment of cancer

06.2018 - andera Life Sciences In portfolio

Tricares

Prothèse de valve tricuspide

03.2017 - andera Life Sciences In portfolio

Avalyn Pharma

Molécule anti-fibrotique inhalée pour le traitement d'une maladie respiratoire rare

06.2017 - andera Life Sciences In portfolio

LogicBio

Thérapie génique pour le traitement de maladies rares pédiatriques

09.2015 - andera Life Sciences Sold

Sanifit

Phytic acid for the treatment of cardiovascular calcification

07.2013 - andera Life Sciences Sold

Oncoethix

Small molecules for haematological cancer treatment

05.2014 - andera Life Sciences Sold

CHASE Pharmaceuticals

Novel approach to increase efficacy and safety of marketed Alzheimer's drugs

12.2009 - andera Life Sciences Sold

Tobira Therapeutics

Mocules for the treatment of inflammatory diseases

01.2019 - andera Life Sciences In portfolio

Exciva

Small molecule for the treatment of behavioral and psychological symptoms of dementia in AD